Share

Market insight in association with

Population boom will boost acute stroke market, particularly in China

The acute ischemic stroke (AIS) market is about to experience growth across the eight major markets (the 8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) from 2017 to 2027. The major barriers to the AIS market growth will be the availability of cheap and established anticoagulants such as warfarin, and the upcoming patent expiries of the branded non-vitamin K antagonist oral anticoagulants (NOACs) within ten years.

Despite this, market sales will increase across the 8MM due to the increasing incidence and prevalence of AIS as well as the anticipated launches of novel, presumably highly priced, neuroprotective drugs and stem cell therapies. China will experience the biggest increase in AIS patient population, according to GlobalData epidemiologists. As a result, China will experience the biggest market growth after the US, despite the lack of the new products launching in this market. GlobalData believes that the China AIS market holds a huge opportunity for drug companies pursuing development of drugs for post-stroke recovery.

AIS results from a complete blockage of a cerebral artery, leading to the death of brain cells and permanent damage. Current treatment of AIS centres around the restoration of blood flow to the brain by thrombolysis using Roche’s Activase (alteplase)—the only thrombolytic drug for AIS—or endovascular treatment to reverse ischemic stroke, or both in combination. After the acute event, antiplatelet, anticoagulant, statin, and antihypertensive drugs are used to prevent stroke recurrence.

A substantial increase in the incidence and prevalence of AIS will be the sole driver of China’s AIS market growth in the next ten years. GlobalData foresees that the single greatest driver of the AIS market in China will be an increase in the incident and prevalent cases of AIS, likely due to China’s ageing population. China was the second biggest AIS market, after the US, in 2017, and will remain the second biggest market in 2027 due to its growing AIS population. The diagnosed incidence of AIS will increase from an estimated 2.3 million stroke patients in 2017, to 3.6 million by 2027, while the prevalent cases of AIS will grow from 5.3 million to 8.0 million in China alone. The biggest barrier to growth of the China AIS market, however, will be the lack of new therapies launching in this market.

Opportunity for stem cell therapy developers to penetrate the China AIS market

Despite the extended therapeutic time window for thrombolysis with Activase and implementation of endovascular treatment, many patients are still left with disabling neurological complications after a stroke. Poor neurological recovery following an AIS event is associated with great socioeconomic burden globally. Organised after-stroke care is particularly poor in China, which results in a high proportion of AIS patients losing their ability to live independently.

According to China key opinion leaders interviewed by GlobalData, the biggest unmet need in China is improving after-stroke care, and therefore there is need for drugs that could reduce disabilities and improve stroke outcomes, especially for those with chronic stroke requiring rehabilitation. GlobalData believes that developers have a great opportunity in the China AIS market to commercialise new products designed to improve stroke outcomes.

For more insight and data, visit the GlobalData Report Store.

Share this article

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue